Presentation
13 March 2024 Development of imaging probes for fluorescence guided surgery of GI and endocrine tumors
Author Affiliations +
Abstract
The ability of the surgeon to accurately visualize tumor margins and identify metastases is necessary for accurate staging and the success of any cancer operation. Fluorescence imaging, because of its high sensitivity, low cost, portability, and real-time capabilities has great potential to improve surgical outcomes. In our laboratory, we have developed a variety of tumor specific antibodies and nanobodies conjugated to near infrared dyes to label GI cancers including pancreatic, colon, and gastric cancers in mouse models of cancer. While most of the studies are pre-clinical in nature, several antibodies and small peptides are now in human clinical trials for fluorescence guided surgery (FGS). In addition to labelling tumors for accurate and complete resection, it is also vital to preserve nearby anatomical structures, such as nerves, to decrease the morbidity of surgery and reduce complications. Preclinical studies that have led to the current technology for fluorescence imaging that is now available in the operating room will be reviewed as well as current clinical trials for FGS.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Michael Bouvet "Development of imaging probes for fluorescence guided surgery of GI and endocrine tumors", Proc. SPIE PC12825, Molecular-Guided Surgery: Molecules, Devices, and Applications X, PC128250X (13 March 2024); https://doi.org/10.1117/12.3009487
Advertisement
Advertisement
KEYWORDS
Tumors

Surgery

Fluorescence imaging

Fluorescence

Cancer

Colorectal cancer

Pancreatic cancer

Back to Top